Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033

Pfizer

Status and phase: Withdrawn; Phase 1

Conditions: Obesity

Treatments: Drug: CP-742,033; Drug: Fenofibrate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00376285

A5431015

Details and patient eligibility

About

The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI of 30-40 kg/m2

Exclusion criteria

• Women of childbearing potential

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind